Skip to content
The Nexus
DossierENTITY

Kelun-Biotech

Coverage of Kelun-Biotech in the Nexus archive.

Earliest in view: May 21 · 21:00 UTCMost recent: May 21 · 21:00 UTC
Co-mentioned in this coverage
Merckorganization1sacituzumab tirumotecantopic1non-small cell lung cancertopic1ASCOorganization1Chinaplace1PD-1 immunotherapytopic1
Recent coverage
  • HEALTHMay 21 · 21:00 UTCSTAT NEWS
    STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows

    Merck and China-based Kelun-Biotech's drug sacituzumab tirumotecan demonstrated a 65% reduction in tumor progression risk in Phase 3 lung cancer trials. The study represents the first successful combination of an antibody-drug conjugate with PD-1 immunotherapy in advanced non-small cell lung cancer patients, with preliminary survival benefits observed.

Kelun-Biotech · Dossier · The Nexus